Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Altimmune Inc

ALT ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$2.94

▲ +2.08%

Market Cap $571.88M · Vol 742.61K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$571.88M

Small Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+39.37%

YoY

RSI (14)

48.91

Momentum

Beta

0.17

vs Market

52W High

$6.43

54.28% below

52W Low

$2.57

14.62% above

Volume

742.61K

Avg 1.08M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

99.58%

Public shares

Shariah Compliance8 STANDARDS

✗ Altimmune Inc (ALT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.55%

+0.34%

+0.68%

-35.10%

YTD

-18.56%

-20.11%

+4.63%

-75.54%

Financials & Valuation

TTM · Annual

Total Revenue	$41.00K
Net Income	$-88,093,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-230,460.98%
Net Profit Margin	-214,860.98%
ROE	N/A
ROA · ROIC	-42.35% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+39.37%
Outstanding Shares	194.52M

Technical Indicators

50-Day SMA	$2.90
200-Day SMA	$3.72
RSI (14)	48.91
Beta	0.17
52-Week High	$6.43
52-Week Low	$2.57

Volume Today	742.61K
Avg Daily Volume (30D)	1.08M
Relative Volume	0.68x
Volatility (10D)	38.11
Volatility (30D)	41.15
Free Float	99.58%

Analyst Consensus

BUY

Current Price $2.94

Mean Target $17.22

52W Low$2.57 52W High$6.43

Current

Target

$2.57 $6.43

Current Analyst target

+485.79% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SNS461

ISINUS02155H2004

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed Phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.